Seat­tle-based Covid-19 vac­cine de­vel­op­er seeks $950M from In­di­an part­ner over trade se­cret theft

Seat­tle-based HDT Bio, which is de­vel­op­ing an saR­NA vac­cine to pre­vent Covid-19, on Mon­day sued In­dia-based Em­cure for $950 mil­lion, say­ing that Em­cure sought to cut ties with HDT, file patents on HDT tech, and go pub­lic on the strength of the vac­cine.

“Em­cure’s Cin­derel­la sto­ry is a fairy tale spun to lure in­vestors to a gener­ics mak­er whose pri­or at­tempt to go pub­lic failed for lack of in­ter­est,” HDT said in its com­plaint filed in Wash­ing­ton state dis­trict court on Mon­day. “The truth is mun­dane: Em­cure stole HDT’s tech­nol­o­gy, which HDT had li­censed to its sub­sidiary Gen­no­va for man­u­fac­ture and dis­tri­b­u­tion in In­dia.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER